Subtopic Deep Dive
Selenium in Cancer Prevention
Research Guide
What is Selenium in Cancer Prevention?
Selenium in Cancer Prevention examines the role of selenium supplementation and dietary intake in reducing cancer incidence through epidemiological evidence, clinical trials like the Nutritional Prevention of Cancer (NPC) study, and mechanisms such as antioxidant protection and apoptosis induction.
Key trials include the NPC study by Clark (1996, 2405 citations), which showed selenium supplementation reduced skin cancer incidence in a double-blind RCT. The SELECT trial by Lippman et al. (2008, 2090 citations) found no prostate cancer risk reduction and potential diabetes risks with high-dose selenium. Rayman (2000, 4099 citations) and Rayman (2012, 3300 citations) review selenium's health benefits, including cancer prevention via selenoproteins.
Why It Matters
Selenium's potential chemopreventive effects influence dietary guidelines and supplementation policies; Clark (1996) demonstrated 37% reduction in non-melanoma skin cancers, guiding nutrition recommendations. Negative SELECT findings by Lippman et al. (2008) highlight risks of high doses in selenium-replete populations, impacting public health trials. Rayman (2012) synthesizes evidence for selenoproteins in DNA repair and apoptosis, informing targeted therapies for prostate and other cancers.
Key Research Challenges
Conflicting Clinical Trial Results
NPC trial by Clark (1996) showed cancer reduction, but SELECT by Lippman et al. (2008) found no benefit and increased risks. Baseline selenium status varies across populations, confounding outcomes. Over 50 trials reviewed in Rayman (2012) underscore need for stratified analyses.
Optimal Dosage Determination
High doses in SELECT (200 μg/day) raised diabetes risk per Lippman et al. (2008), while NPC used 200 μg with benefits (Clark, 1996). Rayman (2000) notes selenoprotein saturation at 40-300 μg/day. Personalized dosing based on status remains unresolved.
Mechanistic Validation in Humans
Selenoproteins aid DNA repair (Papp et al., 2007, 1315 citations), but human causation unclear. Antioxidant effects seen in vitro, yet SELECT failed to confirm (Lippman et al., 2008). Integrating epidemiology with molecular data challenges translation.
Essential Papers
The importance of selenium to human health
Margaret P. Rayman · 2000 · The Lancet · 4.1K citations
Selenium and human health
Margaret P. Rayman · 2012 · The Lancet · 3.3K citations
Effect of Selenium and Vitamin E on Risk of Prostate Cancer and Other Cancers
Scott M. Lippman, Eric A. Klein, Phyllis J. Goodman et al. · 2008 · JAMA · 2.1K citations
clinicaltrials.gov identifier: NCT00006392.
Effects of Selenium Supplementation for Cancer Prevention in Patients With Carcinoma of the Skin
Larry Clark · 1996 · JAMA · 1.9K citations
<h3>Objective.</h3> —To determine whether a nutritional supplement of selenium will decrease the incidence of cancer. <h3>Design.</h3> —A multicenter, double-blind, randomized, placebo-controlled c...
Vitamin E and the Risk of Prostate Cancer
Eric A. Klein, Ian M. Thompson, Catherine M. Tangen et al. · 2011 · JAMA · 1.7K citations
Clinicaltrials.gov Identifier: NCT00006392.
Oxidative stress and male infertility—a clinical perspective
Kelton Tremellen · 2008 · Human Reproduction Update · 1.5K citations
Oxidative stress occurs when the production of potentially destructive reactive oxygen species (ROS) exceeds the bodies own natural antioxidant defenses, resulting in cellular damage. Oxidative str...
Reading Guide
Foundational Papers
Start with Rayman (2000, 4099 citations) for broad selenium health context, then Clark (1996, 2405 citations) NPC trial for positive evidence, and Lippman et al. (2008, 2090 citations) SELECT for null results and risks.
Recent Advances
Rayman (2012, 3300 citations) updates mechanisms; Klein et al. (2011, 1708 citations) extends SELECT vitamin E findings relevant to combo therapies.
Core Methods
RCTs with selenomethionine (200 μg/day, Clark 1996); plasma selenium measurement for status; selenoprotein assays (Papp et al., 2007); meta-regression on cancer incidence.
How PapersFlow Helps You Research Selenium in Cancer Prevention
Discover & Search
Research Agent uses searchPapers('selenium cancer prevention NPC SELECT') to retrieve Clark (1996) and Lippman (2008), then citationGraph to map 2405+ NPC citations; exaSearch uncovers stratified analyses from Rayman (2012); findSimilarPapers on SELECT reveals 50+ supplementation trials.
Analyze & Verify
Analysis Agent applies readPaperContent on Clark (1996) abstracts for NPC hazard ratios, verifyResponse (CoVe) cross-checks claims against Lippman (2008), and runPythonAnalysis extracts meta-analysis stats from Rayman (2012) with GRADE grading for RCT evidence quality.
Synthesize & Write
Synthesis Agent detects gaps like baseline selenium in SELECT via gap detection, flags contradictions between NPC and SELECT; Writing Agent uses latexEditText for trial comparison tables, latexSyncCitations for 10+ papers, and latexCompile for review manuscripts with exportMermaid for trial flowcharts.
Use Cases
"Meta-analyze selenium dose-response from NPC and SELECT trials"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas meta-regression on hazard ratios from Clark 1996 and Lippman 2008) → outputs GRADE-scored forest plot CSV.
"Draft LaTeX review on selenium cancer mechanisms"
Synthesis Agent → gap detection → Writing Agent → latexEditText (insert Rayman 2012 selenoprotein data) → latexSyncCitations (Clark 1996, Papp 2007) → latexCompile → outputs compiled PDF with citations.
"Find analysis code for selenium trial data"
Research Agent → paperExtractUrls (Lippman 2008) → paperFindGithubRepo → githubRepoInspect → outputs R scripts for SELECT survival analysis from clinicaltrials.gov NCT00006392.
Automated Workflows
Deep Research workflow scans 250M+ papers via searchPapers for 'selenium supplementation cancer RCT', synthesizes NPC/SELECT via DeepScan's 7-step CoVe checkpoints with GRADE scoring. Theorizer generates hypotheses on selenoprotein thresholds from Rayman (2000/2012), chaining citationGraph → runPythonAnalysis for dose modeling.
Frequently Asked Questions
What is Selenium in Cancer Prevention?
It studies selenium's role in reducing cancer risk via supplementation trials like NPC (Clark, 1996) and mechanisms including selenoprotein-mediated antioxidant defense (Rayman, 2012).
What are key methods in this subtopic?
Double-blind RCTs like NPC (Clark, 1996; 200 μg/day selenomethionine) and SELECT (Lippman et al., 2008; NCT00006392); epidemiological cohort studies reviewed in Rayman (2000).
What are the most cited papers?
Rayman (2000, 4099 citations) on selenium health; Clark (1996, 2405 citations) NPC trial; Lippman et al. (2008, 2090 citations) SELECT prostate cancer results.
What open problems exist?
Resolving trial contradictions (NPC benefit vs SELECT null); optimal dosing by baseline status; human validation of mechanisms like apoptosis (Papp et al., 2007).
Research Selenium in Biological Systems with AI
PapersFlow provides specialized AI tools for Nursing researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Selenium in Cancer Prevention with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Nursing researchers
Part of the Selenium in Biological Systems Research Guide